Advanced glycation end products: Association with the pathogenesis of diseases and the current therapeutic advances

Current Clinical Pharmacology

Volumn 11, Issue 2, 2016, Pages 118-127

  Ajith, Thekkuttuparambil A ^a   Vinodkumar, Puzhikunathu ^a  

^a AMALA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Advanced glycation end products; Aminoguanidine; Curcumin; Cytokines; Dicarbonyls; Reactive oxygen species; Resveratrol

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALAGEBRIUM; AMINOGUANIDINE; CURCUMIN; MINODRONIC ACID; RESVERATROL; TELMISARTAN; CYTOKINE; FREE RADICAL;

CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASES; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; AGING; ANIMAL; DRUG DESIGN; METABOLISM; PHYSIOLOGY;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; AGING; ANIMALS; CYTOKINES; DRUG DESIGN; FREE RADICALS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS;

EID: 84983775287     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574884711666160511150028     Document Type: Review

References (110)

1. Yan SF, D'Agati V, Schmidt AM, Ramasamy R. Receptor for Advanced Glycation End products (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging. Curr Mol Med 2007; 7: 699-710.
2. Simm A, Wagner J, Gursinsky T, et al. Advanced glycation endproducts: a biomarker for age as an outcome predictor after cardiac surgery? Exp Gerontol 2007; 42: 668-75.
3. Srikanth V, Maczurek A, Phan T, et al. Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. Neurobiol Aging 2011; 32: 763-77.
4. Tan KC, Chow WS, Lam JC, et al. Advanced glycation endproducts in nondiabetic patients with obstructive sleep apnea. Sleep 2006; 29: 329-33.
5. Pertyńska-Marczewska M, Głowacka E, Sobczak M, Cypryk K, Wilczyński J. Glycation end products, soluble receptor for advanced glycation end products and cytokines in diabetic and nondiabetic pregnancies. Am J Reprod Immunol 2009; 61: 175-82.
6. Bartakova V, Kollarova R, Kuricova K, Sebekova K, Belobradkova J, Kankova K. Serum carboxymethyl-lysine, a dominant advanced glycation end product, is increased in women with gestational diabetes mellitus. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2016; 160: 70-5.
7. Dalal M, Ferrucci L, Sun K, et al. Elevated serum advanced glycation end products and poor grip strength in older communitydwelling women. J Gerontol A Biol Sci Med Sci 2009; 64: 132-7.
8. Singh R, Barden A, Mori T, Beilin L. Advanced glycation endproducts: a review. Diabetologia 2001; 44: 129-46.
9. Sell DR, Monnier VM. End stage renal disease and diabetes catalyse the formation of a pentose-derived cross-link form aging human collagen. J Clin Invest 1990; 85: 380-84.
10. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Int Med 2002; 251: 87-101.
11. Vlassara H, Bucala R, Striker L. Pathogenic effect of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 1994; 2: 138-51.
12. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615-25.
13. Baynes JW, Thorpe SR. Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 2000; 28: 1708-16.
14. Cerami C, Founds H, Nicholl I, et al. Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci U S A 1997; 94: 13915-20.
15. Goldberg T, Cai W, Peppa M, et al. Advanced glycoxidation end products in commonly consumed foods.. J Am Diet Assoc 2004; 104: 1287-91.
16. Uribarri J, Woodruff S, Goodman S, et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 2010; 110: 911-16.
17. de Courten B, de Courten MP, Schalkwijk CG, et al. Dietary Advanced Glycation End Products Consumption as a Direct Modulator of Insulin Sensitivity in Overweight Humans: A Study Protocol for a Double-Blind, Randomized, Two Period Cross-Over Trial. JMIR Res Protoc 2015; 4: e93l.
18. de Courten B, de Courten MP, Soldatos G, et al. Diet low in advanced glycation end products increases insulin sensitivity in healthy overweight individuals: a double-blind, randomized, crossover trial. Am J Clin Nutr 2016; 103(6): 1426-33.
19. Koschinsky T, He CJ, Mitsuhashi T, et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A 1997; 94: 6474-9.
20. Smedsrod B, Melkko J, Araki N, Sano H, Horiuchi S. Advanced glycation end products are eliminated by scavenger-receptormediated endocytosis in hepatic sinusoidal Kupffer and endothelial cells. Biochem J 1997; 322: 567-73.
21. Lu C, He JC, Cai W, Liu H, Zhu L, Vlassara H. Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells. Proc Natl Acad Sci U S A 2004; 101: 11767-72.
22. Pinkas A, Aschner M. Advanced Glycation End-Products and Their Receptors: Related Pathologies, Recent Therapeutic Strategies, and a Potential Model for Future Neurodegeneration Studies. Chem Res Toxicol 2016; 29(5): 707-14.
23. Casselmann C, Reimann A, Friedrich I, Schubert A, Silber RE, Simm A. Age-dependent expression of advanced glycation end product receptor genes in the human heart. Gerontology 2004; 50: 127-34.
24. Gugliucci A, Bendayan M. Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia 1996; 39: 149-60.
25. Oleniuc M, Schiller A, Secara I, et al. Evaluation of advanced glycation end products accumulation, using skin autofluorescence, in CKD and dialysis patients. Int Urol Nephrol 2012; 44: 1441-9.
26. Zhang Y, Mei CL, Rong S, et al. Effect of the Combination of Hemodialysis and Hemoperfusion on Clearing Advanced Glycation End Products: A Prospective, Randomized, Two-Stage Crossover Trial in Patients Under Maintenance Hemodialysis. Blood Purif 2015; 40: 127-32.
27. Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 2000; 1498: 99-111.
28. Ramasamy R, Yan SF, Schmidt AM. The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes. Vascul Pharmacol 2012; 57: 160-7.
29. Adeshara KA, Diwan AG, Tupe RS. Diabetes and Complications: Cellular Signalling Pathways, Current Understanding and Targeted Therapies. Curr Drug Targets 2015[Epub ahead of print].
30. Haliwell B, Gutteridge J. Free radicals in Biology and Medicine, 4th ed. Claredon Press, Oxford, 2007, 642-5.
31. Cai W, Li J, Xu JX, et al. Association of 2184AG Polymorphism in the RAGE Gene with Diabetic Nephropathy in Chinese Patients with Type 2 Diabetes. J Diabetes Res 2015; 2015: 310237.
32. Sugimoto K, Yasujima M, Yagihashi S. Role of advanced glycation end products in diabetic neuropathy. Curr Pharm Des 2008; 14: 953-61.
33. Toth C, Rong LL, Yang C, et al. Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy. Diabetes 2008; 57: 1002-17.
34. Radoi V, Lixandru D, Mohora M, Virgolici B. Advanced glycation end products in diabetes mellitus: mechanism of action and focused treatment. Proc Rom Acad Series B 2012: 9-19.
35. Virgolici B, Mohora M, Radoi V, et al. Correlations between dysglycemia, markers of oxidative stress and inflammation in diabetic foot patients. Farmacia 2011; 59: 216-27.
36. Waanders F, Greven WL, Baynes JW, et al. Renal accumulation of pentosidine in non-diabetic proteinuria induced renal damage in rats. Nephrol Dial Transplant 2005; 20: 2060-70.
37. Chung AC, Zhang H, Kong YZ, et al. Advanced glycation endproducts induce tubular CTGF via TGF-beta-independent Smad3 signaling. J Am Soc Nephrol 2010; 21: 249-60.
38. Samarakoon R, Dobberfuhl AD, Cooley C, et al. Induction of renal fibrotic genes by TGF-β1 requires EGFR activation, p53 and reactive oxygen species. Cell Signal 2013; 25: 2198-209.
39. Galler A, Muller G, Schinzel R, Kratzsch J, Kiess W, Munch G. Impact of metabolic control and serum lipids on the concentration of advanced glycation end products in the serum of children and adolescents with type 1 diabetes, as determined by fluorescence spectroscopy and nepsilon-(carboxymethyl)lysine ELISA. Diabetes Care 2003; 26: 2609-15.
40. Yap FY, Kantharidis P, Coughlan MT, Slattery R, Forbes JM. Advanced glycation end products as environmental risk factors for the development of type 1 diabetes. Curr Drug Targets 2012; 13: 526-40.
41. Miura J, Yamagishi Si, Uchigata Y, et al. Serum levels of noncarboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes. J Diabetes Complications 2003; 17: 16-21.
42. Uribarri J, Tuttle KR. Advanced Glycation End products and nephrotoxicity of high-protein diets. CJASN 2006; 1: 1293-9.
43. Shaikh S, Nicholson LF. Advanced glycation end products induce in vitro cross-linking of alpha-synuclein and accelerate the process of intracellular inclusion body formation. J Neurosci Res 2008; 86: 2071-82.
44. Sajithlal GB, Chithra P, Chandrakasan G. Advanced glycation end products induce cross linking of collagen in vitro. Biochim Biophys Acta 1998: 1407; 215-24.
45. Haus JM, Carrithers JA, Trappe SW, Trappe TA. Collagen, crosslinking, and advanced glycation end products in aging human skeletal muscle. J Appl Physiol 2007; 103: 2068-76.
46. Berg TJ, Snorgaard O, Faber J, et al. Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes. Diabetes Care 1999; 22: 1186-90.
47. Hyogo H, Yamagishi S, Iwamoto K, et al. Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007; 22: 1112-9.
48. Lin J, Tang Y, Kang Q, et al. Curcumin eliminates the inhibitory effect of advanced glycation end-products (AGEs) on gene expression of AGE receptor-1 in hepatic stellate cells in vitro. Lab Invest 2012; 92: 827-41.
49. Sims TJ, Rasmussen LM, Oxlund H, Bailey AJ. The role of glycation cross-links in diabetic vascular stiffening. Diabetologia 1996; 39: 946-51.
50. Bucala R, Mitchell R, Arnold K, et al. Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptor. J Biol Chem 1995; 270: 828-32.
51. Sakata N, Meng J, Takebayashi S. Effects of advanced glycation end products on the proliferation and fibronectin production of smooth muscle cells. J Atheroscler Thromb 2000; 7: 169-76.
52. Klein RL, Laimins M, Lopes-Virella MF. Isolation, characterization, and metabolism of the glycated and nonglycated subfractions of low-density lipoproteins isolated from type I diabetic patients and nondiabetic subjects. Diabetes 1995; 44: 1093-8.
53. Daffu G, Shen X, Senatus L, et al. RAGE Suppresses ABCG1-Mediated Macrophage Cholesterol Efflux in Diabetes. Diabetes 2015; 64: 4046-60.
54. Lin JA, Wu CH, Lu CC, Hsia SM, Yen GC. Glycative stress from advanced glycation end products (AGEs) and dicarbonyls: An emerging biological factor in cancer onset and progression. Mol Nutr Food Res 2016 [Epub ahead of print].
55. Leclerc E, Vetter SW. The role of S100 proteins and their receptor RAGE in pancreatic. Biochim Biophys Acta 2015; 1852: 2706-11.
56. Bao JM, He MY, Liu YW, et al. AGE/RAGE/Aktpathway contributes to prostate cell proliferation by promoting Rb phosphorylation and degradation. Am J Cancer Res 2015; 5: 1741-50.
57. Sakellariou S, Fragkou P, Levidou G, et al. Clinical significance of AGE-RAGE axis in colorectal cancer: associations with glyoxalase-I, adiponectin receptor expression and prognosis. BMC Cancer 2016; 16: 174.
58. Yamagishi S, Matsui T, Nakamura K. Possible involvement of tobacco-derived advanced glycation end products (AGEs) in an increased risk for developing cancers and cardiovascular disease in former smokers. Med Hypotheses 2008; 71: 259-61.
59. Li XH, Du LL, Cheng XS, et al. Glycation exacerbates the neuronal toxicity of β-amyloid. Cell Death Dis 2013; 4: e673.
60. Origlia N, Righi M, Capsoni S, et al. Receptor for advanced glycation end product-dependent activation of p38 mitogenactivated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction. J Neurosci 2008; 28: 3521-30.
61. Kim Y, Kim C, Son SM, et al. The novel RAGE interactor PRAK is associated with autophagy signaling in Alzheimer's disease pathogenesis. Mol Neurodegener 2016; 11: 4.
62. Chen C, Li XH, Tu Y, et al. Aβ-AGE aggravates cognitive deficit in rats via RAGE pathway. Neurosci 2014; 257: 1-10.
63. Saudek DM, Kay J. Advanced glycation endproducts and osteoarthritis. Curr Rheumatol Rep 2003; 5: 33-40
64. Verzijl N, DeGroot J, Ben ZC, et al. Cross linking by advanced glycation end products increases the stiffness of the collagen network in human articular cartilage: a possible mechanism through which age is a risk factor for osteoarthritis. Arthritis Rheum 2002; 46: 114-23.
65. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006; 114: 597-605.
66. DeGroot J, Verzijl N, Jacobs KM, et al. Accumulation of advanced glycation endproducts reduces chondrocyte-mediated extracellular matrix turnover in human articular cartilage. Osteoarthritis Cartilage 2001; 9: 720-6.
67. Senolt L, Braun M, Olejarova M, Forejtova S, Gatterova J, Pavelka K. Increased pentosidine, an advanced glycation end product, in serum and synovial fluid from patients with knee osteoarthritis and its relation with cartilage oligomeric matrix protein. Ann Rheum Dis 2005; 64: 886-90.
68. Hein GE, Kohler M, Oelzner P, Stein G, Franke S. The advanced glycation end product pentosidine correlates to IL-6 and other relevant inflammatory markers in rheumatoid arthritis. Rheumatol Int 2005; 26: 137-41.
69. Wu Q, Zhong ZM, Zhu SY, et al. Advanced oxidation protein products induce chondrocyte apoptosis via receptor for advanced glycation end products-mediated, redox-dependent intrinsic apoptosis pathway. Apoptosis 2016; 21: 36-50.
70. Glenn JV, Stitt AW. The role of advanced glycation end products in retinal ageing and disease. Biochim Biophys Acta 2009; 1790: 1109-16.
71. Kandarakis SA, Piperi C, Topouzis F, Papavassiliou AG. Emerging role of advanced glycation-end products (AGEs) in the pathobiology of eye diseases. Prog Retin Eye Res 2014; 42: 85-102.
72. Kandarakis SA, Piperi C, Moschonas DP, et al. Dietary glycotoxins induce RAGE and VEGF up-regulation in the retina of normal rats. Exp Eye Res 2015; 137: 1-10.
73. Puddu A, Sanguineti R, Durante A, Nicolo M, Viviani GL. Vascular endothelial growth factor-C secretion is increased by advanced glycation end-products: possible implication in ocular neovascularization. Mol Vis 2012; 18: 2509-17.
74. Brownlee M, Vlassara H, Kooney T, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986; 232: 1629-32.
75. Freedman BIWJ, Cartwright K, Bain RP, et al. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II) Control. Clin Trials 1999; 20: 493-510.
76. Bolton WK, Cattran DC, Williams ME, et al. Randomized trial of an inhibitor of formation of advanced glycation endproducts in diabetic nephropathy. Am J Nephrol 2004; 24: 32-40.
77. Cooper ME, Thallas V, Forbes J, et al. The cross-link breaker, Nphenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation. Diabetologia 2000; 43: 660-4.
78. Vasan S, Foiles PG, Founds HW. Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links. Expert Opin Investig Drugs 2001; 10: 1977-87.
79. Krautwald M, Leech D, Horne S, et al. The advanced glycation end product-lowering agent ALT-711 is a low affinity inhibitor of thiamine diphosphokinase. Rejuvenation Res 2011; 14: 383-91.
80. Joshi D, Gupta R, Dubey A, et al. TRC4186, a novel AGE-breaker, improves diabetic cardiomyopathy and nephropathy in Ob-ZSF1 model of type 2 diabetes. J Cardiovasc Pharmacol 2009; 54: 72-81.
81. Figarola JL, Shanmugam N, Natarajan R, Rahbar S. Antiinflammatory effects of the advanced glycation endproduct inhibitor LR-90 in human monocytes. Diabetes 2007; 56: 647-55.
82. Takeuchi M, Takino J, Yamagishi S. Involvement of the Toxic AGEs (TAGE)-RAGE system in the pathogenesis of Diabetic vascular complications: A Novel Therapeutic Strategy. Curr Drug Targets 2010; 11: 1468-82.
83. Yamagishi S, Nakamura K, Matsui T, Takeuchi M. Minodronate, a nitrogen-containing bisphosphonate, is a promising remedy for treating patients with diabetic retinopathy. Med Hypotheses 2006; 66: 273-5.
84. Yamagishi S, Matsui T, Nakamura K, Takeuchi M. Minodronate, a nitrogen-containing bisphosphonate, inhibits advanced glycation end product-induced vascular cell adhesion molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation. Int J Tissue React 2005; 27: 189-95.
85. Yoshida T, Yamagishi S, Nakamura K, et al. Telmisartan inhibits AGE-induced C-reactive protein production through down regulation of the receptor for AGE via peroxisome proliferatoractivated receptor gamma activation. Diabetologia 2006; 49: 3094-9.
86. Thomas MC, Tikellis C, Burns WM, et al. Interactions between rennin angiotensin system and advanced glycation in the kidney. J Am Soc Nephrol 2005; 16: 2976-84.
87. Ajith TA, Harikumar KB, Thasna H, Sabu MC, Babitha NV. Proapoptotic and antitumor activities of the HMG-CoA reductase inhibitor, lovastatin, against Dalton's lymphoma ascites tumor in mice. Clin Chim Acta 2006; 366: 322-8.
88. Ajith TA, Riji T, Anu V. In vitro anti-oxidant and DNA protective effects of the novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin. Clin Exp Pharmacol Physiol 2008; 35: 625-9.
89. Jinnouchi Y, Yamagishi S, Takeuchi M, et al. Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes. Clin Exp Med 2006; 6: 191-3.
90. Tam HL, Shiu SW, Wong Y, Chow WS, Betteridge DJ, Tan KC. Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes. Atherosclerosis 2010; 209: 173.
91. Feng B, Xu L, Wang H, et al. Atorvastatin exerts its antiatherosclerotic effects by targeting the receptor for advanced glycation end products. Biochim Biophys Acta 2011; 1812: 1130-7.
92. Maltais JS, Simard E, Froehlich U, Denault JB, Gendron L, Grandbois M. iRAGE as a novel carboxymethylated peptide that prevents advanced glycation end product-induced apoptosis and endoplasmic reticulum stress in vascular smooth muscle cells. Pharmacol Res 2015; 104: 176-85.
93. Mizutani K, Ikeda K, Yamori Y. Resveratrol inhibits AGEsinduced proliferation and collagen synthesis activity in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Biochem Biophysl Res Commun 2000; 274: 61-7.
94. Tang Y. Curcumin eliminates the effect of advanced glycation endproducts (AGEs) on the divergent regulation of gene expression of receptors of AGEs by interrupting leptin signaling. Lab Invest 2014; 94: 503-16.
95. Nakashima K, Miyashita H, Yoshimitsu H, et al. Two new prenylflavonoids from Epimedii Herba and their inhibitory effects on advanced glycation end-products. J Nat Med 2016; 70: 290-5.
96. Joglekar MV, Panaskar SN, Arvindekar AU. Inhibition of advanced glycation end product formation by cymene-A common food constituent. J Funct Foods 2014; 6: 107-15.
97. Lee JY, Oh JG, Kim JS, Lee KW. Effects of chebulic acid on advanced glycation endproducts-induced collagen cross-links. Biol Pharm Bull 2014; 37: 1162-7.
98. Zafar H. Inhibition of protein glycation and advanced glycation end products by ascorbic acid. African J Biotechnol 2012; 11: 51.
99. Abdul HM, Butterfield, DA. Involvement of PI3K/PKG/ERK1/2 signaling pathways in cortical neurons to trigger protection by cotreatment of acetyl-L-carnitine and alpha-lipoic acid against HNE-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease. Free Radic Biol Med 2007; 42: 371-84.
100. Guiotto A, Calderan A, Ruzza P, Borin G. Carnosine and carnosinerelated antioxidants: a review. Curr Med Chem 2005; 12: 2293-315.
101. Ashraf JM, Shahab U, Tabrez S, Lee EJ, Choi I, Ahmad S. Quercetin as a finer substitute to aminoguanidine in the inhibition of glycation products. Int J Biol Macromol 2015; 77: 188-92.
102. Bierhaus A, Chevion S, Chevion M, et al. Advanced glycation end product-induced activation of NF-kappaB is suppressed by alphalipoic acid in cultured endothelial cells. Diabetes 1997; 46: 1481-90.
103. Chen S, Yin L, Xu Z, et al. Inhibiting receptor for advanced glycation end product (AGE) and oxidative stress involved in the protective effect mediated by glucagon-like peptide-1 receptor on AGE induced neuronal apoptosis. Neurosci Lett 2015; 612: 193-8.
104. Ahmad S, Shahab U, Baig MH, et al. Inhibitory effect of metformin and pyridoxamine in the formation of early, intermediate and advanced glycation end-products. PLoS One 2013; 8: e72128.
105. Ruggiero-Lopez D, Lecomte M, Moinet G, Patereau G, Lagarde M, Wiernsperger N. Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation. Biochem Pharmacol 1999; 58: 1765-73.
106. Kiho T, Kato M, Usui S, Hirano K. Effect of buformin and metformin on formation of advanced glycation end products by methylglyoxal. Clin Chim Acta 2005; 358: 139-45.
107. Koyama Y, Takeishi Y, Niizeki T, et al. Soluble Receptor for advanced glycation end products (RAGE) is a prognostic factor for heart failure. J Card Fail 2008; 14: 133-9.
108. Koyama Y, Takeishi Y, Arimoto T, et al. High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure. J Card Fail 2007; 13: 199-206.
109. Mishra N, Saxena S, Shukla RK, et al. Association of serum Nε-Carboxymethyl lysine with severity of diabetic retinopathy. J Diabetes Complications 2016; 30: 511-7.
110. Yamagishi S, Nakamura K, Inoue H, Kikuchi S, Takeuchi M. Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer's disease. Med Hypotheses 2005; 64: 1205-7.